1Pierce WM, Leonard WC. Bone targeted inhibitors of carbonic anhydrase [P]. Eur Patent: 201057, 1986-11-12.
2Perrin RA. Binding of tetracycline to bone [J]. Nature, 1965,208(11):787-788.
3Misra DD. Adsorption and orientation of tetracycline on hydroxyapatite [J]. Calcif Tissue Int, 1991,48(5):362-367.
4Bando N, Kawai T, Hamazaki T, et al. Preparation of tetracycline derivatives as collagenase inhibitors [P]. Jpn Pat: 04178359, 1992-06-25.
5Hanne B, David R. Conjugated for targeted delivery of bone growth factors[P]. Eur Pat: 512844, 1992-11-11.
6a. Zheng H, Weng LL. The compound that can be used to prepare bone-targeted drugs bearing estrogen structure [P]. China Pat: 94111687.5, 1993-11-09.b. Zheng H, Weng LL. Bone resorption inhibition/osteogenesis promotion pharmaceutical composition [P]. US Pat: 5698542, 1997-12-16.
7Orme MW, Labroo VM. Synthesis of α-estradiol-3-benzoate-17-(succinyl-12α-tetracycline): a potential bone-seeking estrogen[J]. Bioorg Med Chem Lett, 1994,4(11):1375-1380.
8Thompson WJ, Thompson DD, Anderson PS, et al. Polymalonic acids as bone affinity agents [P]. Eur Pat: 341961, 1989-11-15.
9Fleisch H. Bisphosphonates: Mechanisms of action [J]. Endocr Rev, 1998,19(1):80-100.
10Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanisms of action of bisphosphonates [J]. Bone, 1999,24(5):73-79(suppl).
